gemcitabine has been researched along with Myelodysplastic Syndromes in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
De Stefano, V; Leone, G; Mario, AD; Mele, L; Pagano, L | 1 |
1 trial(s) available for gemcitabine and Myelodysplastic Syndromes
Article | Year |
---|---|
Use of gemcitabine (GEM) in advanced myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2001 |
1 other study(ies) available for gemcitabine and Myelodysplastic Syndromes
Article | Year |
---|---|
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |